🏢 官网IRERASCodex · 实盘不做把握 7/10
北京时间·🕒 发布 04:01:00时区推断·⟳ 抓取 04:04:28回填·⚡ 决策 07-16 04:05:37·103.8 天前
Erasca完成已定价的增发交割，承销商全额行使超额配售权
本次只是7月13日已公告并定价增发的交割完成，新增信息主要是超额配售权全额行使和总募资额升至约6.325亿美元。
📄 原文ERAS↗ 原文
Skip to main navigation About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder's Let…
不做 Erasca（ERAS.US）
不做：这是已定价增发的交割完成公告，核心条款7月13日已公开；融资完成与稀释影响混合，缺少新的临床/商业化增量，不能形成明确同向交易。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司先公告拟发行5亿美元普通股并授予承销商额外购买权，融资事件从此时开始进入市场预期。
- 公司公告增发定价为17.50美元、31,428,572股、预计募资5.50亿美元，并预计7月15日交割。
- 媒体转载定价公告，说明融资条款已在正式交割前向市场扩散。
- 公司公告交割完成，含承销商全额行使4,714,285股超额配售权，总募资约6.325亿美元。市场反应:公告发生在美股收盘后，连续交易不可成交。
关键理由
- 本次只是7月13日已公告并定价增发的交割完成，新增信息主要是超额配售权全额行使和总募资额升至约6.325亿美元。
- 融资有助于延长研发资金 runway，但用途为研发、营运资金和一般公司用途，没有新增临床数据、合作授权、订单或可量化商业化增量。
- 对股价的一阶影响偏稀释/融资完成中性，且定价和预计交割日期两天前已公开，当前没有足够新的同向交易 edge。
主要风险
- 若市场把全额超额配售理解为机构需求强，可能带来短线情绪支撑，但这不是足够强的基本面催化。
- 临床阶段生物科技公司后续走势更依赖管线数据读出和监管进展，本次融资交割本身难以支撑可回测的方向性交易。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-13 · 影响 weakens
反向证据是核心融资条款已提前两天公告，当前交割完成不构成新的临床或商业化利好。
检索:Erasca pricing upsized public offering July 13 2026 $17.50 原文 ↗
原文全文
展开原文 · 6,195 字
Skip to main navigation
About
People
Science
Pipeline
Patients
Investors
Careers
Overview
Vision & Values
Founder's Letter
Contact
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
R&D Advisory Board
RAS/MAPK Pathway
MAPKlamp & More
Presentations & Publications
Pipeline
Programs
Clinical Trials
Patients & Caregivers
Clinical Trials
Corporate Overview
News & Events
Stock Information
Corporate Governance
Financial Information
Investor Resources
Dynamic Culture
Values & Attributes
Competitive Benefits
Open Positions
Stay in Touch
858.465.6511
info@erasca.com
News & Events
News Release Details
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
07.15.2026
PDF Version
SAN DIEGO , July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 36,142,857 shares of its common stock, including 4,714,285 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $17.50 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $632.5 million . All of the shares of common stock sold in the public offering were sold by Erasca .
Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI acted as joint book-running managers for the offering.
The securities described above were offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) on July 13, 2026 and automatically became effective upon filing.
A final prospectus supplement relating to this offering has been filed with the SEC . The offering was made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC , c/o Broadridge Financial Solutions, 1155 Long Island Avenue , Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com ; Morgan Stanley & Co. LLC , Attention: Prospectus Department, 180 Varick Street , 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com ; Jefferies LLC , Attention: Equity Syndicate Prospectus Department , 520 Madison Avenue , New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; and Evercore Group L.L.C. , Attention: Equity Capital Markets , 55 East 52nd Street , 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com . Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at http://www.sec.gov .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the anticipated use of proceeds from the public offering. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
Contact Us
858.465.6511
info@erasca.com
Location
ERASCA, INC.
3115 Merryfield Row
Suite 300
San Diego, CA 92121
Terms of Use
Privacy Policy
Erasca Foundation
Erasca Ventures
© 2026 Erasca ® , Inc. All rights reserved.
About
People
Science
Pipeline
Patients
Investors
Careers
Overview
Vision & Values
Founder's Letter
Contact
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
R&D Advisory Board
RAS/MAPK Pathway
MAPKlamp & More
Presentations & Publications
Pipeline
Programs
Clinical Trials
Patients & Caregivers
Clinical Trials
Corporate Overview
News & Events
Stock Information
Corporate Governance
Financial Information
Investor Resources
Dynamic Culture
Values & Attributes
Competitive Benefits
Open Positions
Stay in Touch
858.465.6511
info@erasca.com
News & Events
News Release Details
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
07.15.2026
PDF Version
SAN DIEGO , July 15, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 36,142,857 shares of its common stock, including 4,714,285 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $17.50 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $632.5 million . All of the shares of common stock sold in the public offering were sold by Erasca .
Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes.
J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI acted as joint book-running managers for the offering.
The securities described above were offered by Erasca pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with the Securities and Exchange Commission (SEC) on July 13, 2026 and automatically became effective upon filing.
A final prospectus supplement relating to this offering has been filed with the SEC . The offering was made only by means of a prospectus supplement and accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC , c/o Broadridge Financial Solutions, 1155 Long Island Avenue , Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com ; Morgan Stanley & Co. LLC , Attention: Prospectus Department, 180 Varick Street , 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com ; Jefferies LLC , Attention: Equity Syndicate Prospectus Department , 520 Madison Avenue , New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; and Evercore Group L.L.C. , Attention: Equity Capital Markets , 55 East 52nd Street , 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com . Electronic copies of the final prospectus supplement and accompanying prospectus are also available on the website of the SEC at http://www.sec.gov .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Forward Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the anticipated use of proceeds from the public offering. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Source: Erasca, Inc.
Contact Us
858.465.6511
info@erasca.com
Location
ERASCA, INC.
3115 Merryfield Row
Suite 300
San Diego, CA 92121
Terms of Use
Privacy Policy
Erasca Foundation
Erasca Ventures
© 2026 Erasca ® , Inc. All rights reserved.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。